Terminated PHASE2 INTERVENTIONAL 5-arm NCT00123292

Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion

An Open-label, Ascending-dose, Clinical Trial of Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion

Sponsor: ThromboGenics

Conditions Arterial Occlusive Diseases

Interventions Microplasmin

Updated 5 times since 2017 Last updated: Apr 4, 2014 Started: Mar 31, 2005 Primary completion: Jun 30, 2007 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor's decision not to pursue development of uPLi for vascular conditions

Other terminated trials from ThromboGenics

See all terminations from ThromboGenics

Other Arterial Occlusive Diseases trials with similar outcome

Browse all Arterial Occlusive Diseases trials

A PHASE2 clinical study on Arterial Occlusive Diseases, this trial is terminated or withdrawn. The trial is conducted by ThromboGenics and has accumulated 5 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ThromboGenics

Data source: ThromboGenics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leuven, Belgium